Sun, Dec 21, 2014, 4:20 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Endocyte, Inc. (ECYT) Message Board

  • tempestdog743 tempestdog743 Nov 4, 2012 12:32 PM Flag

    ECYT working with scientist at UCSB on m-TOR conjugate for PKD

    The folate-conjugate model has a solid basis. To get the full article type a few words into your browser from the excerpt below:
    Endocyte chemically synthesized a new version of rapamycin called folate-conjugated rapamycin (FC-rapa). Weimbs' laboratory tested this new drug and found that it was still highly effective in preventing kidney cyst growth in mice with PKD, but that it had fewer systemic side effects compared to regular rapamycin. The results suggest that FC-rapa could also be effective in human PKD patients without causing the significant unwanted side effects of regular rapamycin.

    Sentiment: Buy

 
ECYT
6.24-0.10(-1.50%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.